

# Cell-free Directed Evolution of a Protease in Microdroplets at Ultrahigh Throughput

Josephin M. Holstein,<sup>1</sup> Christian Gylstorff,<sup>1,†</sup> & Florian Hollfelder<sup>1\*</sup>

<sup>1</sup> Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge, CB2 1GA, UK

*Protein engineering, directed evolution, microfluidics, ultrahigh throughput, cell-free protein synthesis*

---

**ABSTRACT:** Compartmentalization of single genes in water-in-oil emulsion droplets is a powerful approach to create millions of reactors for enzyme library selections. When these droplets are formed at ultrahigh throughput in microfluidic devices, their perfect monodispersity allows quantitative enzyme assays with a high precision readout. However, despite its potential for high quality cell-free screening experiments, previous demonstrations of enrichment have never been successfully followed up by actual enzyme library selections in monodisperse microfluidic droplets. Here we develop a three-step workflow separating three previously incompatible steps that thus far could not be carried out at once: first droplet-compartmentalized DNA is amplified by rolling circle amplification, and only after completion of this step reagents for *in vitro* protein expression and finally substrate are added *via* picoinjection. The segmented workflow is robust enough to allow the first *in vitro* evolution in droplets, improving the protease Savinase<sup>®</sup> that is toxic to *E. coli* for higher activity and identifying a 5-fold faster enzyme.

---

Directed evolution has emerged as a powerful approach to protein engineering that complements rational design. One key to success in the random combinatorial exploration of protein sequence diversity is the ability to screen large numbers of library members, at low cost and preferably automatically at ultrahigh throughput. Sequence space is vast and only sparsely populated with ‘islands’ of desired function and reaching them relies on chance.<sup>1</sup> *In vivo* selections (e.g. for survival) provide ready access to testing of large libraries - but may be compromised by incompatibility with the host organism and encumbered by possible diversity loss of libraries due to low transformation efficiency. *In vitro* systems are required to improve the intrinsic properties of a protein by overcoming such constraints in order to explore larger fractions of sequence bias-free without host interference. Compartmentalization of genes into water-in-oil emulsion droplets, akin to artificial single purpose cell-like structures, provides a completely artificial format for combining genotype and phenotype.<sup>2</sup> Highly monodisperse droplets can be generated and analysed in an automated and highly controlled way in microfluidic devices and allow a massive scale-down to picoliter volumes along with a massive scale-up of screening throughput to >10<sup>7</sup> candidates per day.<sup>3-6</sup> However, a demonstration of its utility in an actual library selection in this quantitative *in vitro* format is still lacking.

Here we address the conspicuous absence of a complete *in vitro* directed evolution campaign in monodisperse microfluidic droplets. Early *in vitro* compartmentalization directed evolution campaigns in polydisperse droplets had been successful,<sup>7</sup> but often relied on modification of the coding DNA (or conjugates) as the readout of activity and were limited to improvement of already rather active enzymes. Systems for


microfluidic droplet evolution on chip using *in vitro* expression systems have been developed, but only enrichment experiments have been documented.<sup>8,9</sup> Enrichment experiments are often used to validate a workflow, but do not require the selection and recovery of single catalyst genes (in a sea of genes that are not selected), i.e. circumstances typical for the low hit rates in a library experiment. Also, enrichment experiments using an *in vitro* workflow, in which each droplet is filled with multiple copies of a gene at the outset<sup>9</sup> circumvent key challenges of a complete directed evolution that starts with Poisson-distribution of single gene copies of library members. Such a true library evolution experiment in droplets has indeed not been reported thus far. However, *in vitro* expression is possible from single genes,<sup>10</sup> but DNA amplification by PCR<sup>8</sup> or by isothermal amplification<sup>11</sup> increases the number of expression templates, leading to more enzyme molecules and more detectable product. Amplification will also make it easier to recover selected hits. Coordinating DNA amplification, *in vitro* expression and enzymatic reaction is tricky, because of droplet stability and device complexity in a PCR-based protocol that requires heating/cooling steps in thermocycling, or – in the case of isothermal amplification – because of potential cross-inhibition amongst more than 70 components that are present at once in droplet compartments after all addition steps (shown in Fig. 1).

In this work we demonstrate how controlled, stepwise on-chip addition of the components for these three processes leads to a robust workflow that remedies the current impasse in *in vitro* evolution in microfluidic droplets. We set out to evolve Savinase<sup>®</sup>, a subtilisin-like protease naturally secreted by the alkalophilic bacterium *Bacillus lentus* for nutrition and defense<sup>12</sup> and commercially developed for the detergent

industry.<sup>13, 14</sup> Its multiple uses in fine chemical synthesis, washing powder and other biotechnological applications explain why it is produced on a multi-ton-scale. This enzyme class is covered by numerous patents, yet no directed evolution has

been reported. The expression of Savinase<sup>®</sup> in *E. coli* is not possible due to its acute cytotoxicity. The possible alternative of using *B. subtilis* as a directed evolution host would limit the library

## 1. Library construction




**Figure 1.** Functional screening for protease activity using microfluidic droplets. Single plasmids of a randomized Savinase<sup>®</sup> library (1) were compartmentalized in picolitre water-in-oil droplets (2) together with reagents to perform rolling circle amplification (RCA, 3). After an off-chip incubation of emulsion droplets, reagents for *in vitro* transcription and translation were added stepwise (4). Droplets were incubated off chip for another four hours at 37 °C before the fluorogenic casein substrate was picoinjected (5). Emulsion droplets were then re-injected into a sorting device and strongly fluorescent droplets were collected (6). Selected droplets were de-emulsified and RCA product was recovered followed by restriction and ligation (7). Plasmids containing DNA sequences of active catalysts were transformed into *B. subtilis*, re-screened and sequenced (8) to identify improved catalysts. For further enrichment, iterative selections lead to improved enzyme variants. The three key steps that had to be separated in this work to achieve successful selection of proteases with increased activity (overcoming previous limitations) are highlighted by the central box.

size due to its poor transformation efficiency (of typically only hundreds<sup>15</sup>) compared to the throughput of millions in droplet microfluidics. Therefore cell-free protein synthesis is necessary to evolve this enzyme. We designed an ultrahigh-throughput screening platform for *in vitro* directed evolution of Savinase<sup>®</sup> that is illustrated in Figure 1. In a first step single genes (as plasmids or circularized genes containing a T7 promoter as well as a ribosome-binding site) were encapsulated on-chip into monodisperse droplets (~14 pL). Starting with these 'monoclonal' droplets, single gene copies were amplified by rolling circle amplification (RCA). RCA uses random hexamer primers and can potentially amplify any DNA in a non-specific manner.<sup>16</sup> This isothermal process is easier to handle in a device compared to PCR that requires heating modules<sup>17</sup> and avoids droplet coalescence at elevated temperatures. While higher  $\Phi 29$  DNA polymerase concentrations are attractive (e.g. 0.07 pg/ $\mu$ L DNA leads to up to 30,000 copies per gene),<sup>11</sup> strong inhibition of subsequent *in vitro* expression was observed at the highest possible  $\Phi 29$  concentration (500 nM), along with droplet destabilization (see Supplementary Information, SI; Figure S1). The balance between optimal DNA amplification and droplet stability was obtained by using a  $\Phi 29$  DNA polymerase concentration of 100 nM and performing RCA for six hours at 30 °C. Given RCA inhibition by the reagents used for *in vitro* transcription and translation (IVTT) (Figure S2) and the requirement of different incubation temperatures for

optimal performance of *both* processes, these steps were performed separately. To achieve the separation of RCA and IVTT in one microfluidic device, a design that first injected IVTT components (PURE)<sup>18</sup> into droplets was used. Defined volumes (equal to the volume of the droplet; varying between experiments but typically in the range of ~10-15 pL) were introduced into surfactant-stabilized droplets at rates of 1 kHz using electro-microfluidic picoinjector.<sup>19</sup> After addition of IVTT, droplets were incubated off-chip for another four hours at 37 °C. To start the reaction under controlled conditions (i.e. after completion of amplification and expression) and in a pH range that is not necessarily compatible with the preparatory steps, the fluorogenic substrate (a BODIPY<sup>®</sup>-labelled casein that generates fluorescence after cleavage) was picoinjected (~20-30 pL at 0.5 kHz). A 2-fold higher green fluorescent signal (compared to the simultaneous injection of IVTT mixture and casein substrate) was obtained by adding the substrate after enzyme production (Figure S3). After addition of the substrate, the droplets were incubated off-chip to allow for hydrolytic cleavage. Starting with single genes in monoclonal and monodisperse droplets, followed by addition of identical volumes of IVTT and substrate, the equal expression and assay conditions in each droplet suggest a level playing field for subsequent screening. At the completion of an incubation period of three days, droplets were re-injected into a sorting device and the brightest ones were selectively extracted by fluorescence-activated droplet sorting (FADS)<sup>20</sup> to select active proteases. A control

experiment demonstrates that the complex workflow was absolutely necessary to create a viable assay: adding all reagents at once into droplets in a standard flow focusing device design<sup>21,22</sup> produced no measurable product (Figures S1, S2, S3), suggesting that fine-tuning of the concentration, conditions and order of addition was crucial to overcome the incompatibility of different reagents and bring about the reaction product of Savinase<sup>®</sup> at detectable levels.

The workflow was validated by a sorting experiment to enrich droplets expressing Savinase<sup>®</sup> wildtype (sav-wt) from an excess of droplets producing the esterase EstB, which is an enzyme that is not active on the fluorogenic casein substrate. Both DNA constructs were mixed in a 1:250 ratio and the




**Figure 2** Generation of six different libraries of the serine protease Savinase<sup>®</sup> (pdb 1SVN) and screening results. (A) 9 - 11 residues of six different loops located around the active site (indicated in red, orange, yellow, green, blue, and purple) were mutated using a Slonomics approach to generate libraries 1-6. The catalytic triad is highlighted in dark blue (D32, H64 and S221). Two calcium ions are shown as yellow balls. (B) Overlay of fluorescent and bright field microscope images showing droplets exhibiting enzymatic activity. The casein substrate (20  $\mu\text{g}/\mu\text{L}$ ) was incubated either with 1  $\mu\text{M}$  of sav-wt (+sav-wt) or without protease (-sav-wt). Scale bars: 100  $\mu\text{m}$ . (C) and (E) Histograms of the fluorescence signal distribution in fluorescence-activated droplet sorting (FADS) of droplets screened for Savinase<sup>®</sup> activity after three days of incubation at room temperature in darkness. The sorting gate was set up, so that droplets showing increased fluorescence over the population average were selected. A fluorescence image of a droplet population with typically few hits in a library is shown in Fig. S4. (D) and (F) Enrichment of positive hits after droplet sorting. After DNA recovery and transformation of *B. subtilis*, 88 colonies were randomly picked from the unsorted original library and the sorted samples, followed by an assay against the fluorogenic casein substrate. The data were normalized to the rate of sav-wt. The bar graphs give a comparison of variants showing higher activity (activity > wt) or lower activity (activity < wt) compared to wt.

abundance of sav-wt before and after sorting was analyzed via quantitative PCR (qPCR). The initial content of 0.4% sav-wt plasmid was increased to 99% sav-wt plasmids after sorting, giving an enrichment of 250-fold (calculated according to Zinchenko *et al.*<sup>23</sup>) or 300,000-fold (calculated according to Baret *et al.*<sup>20</sup>, Table S1, Figures S5 and S6).

Next, six Savinase<sup>®</sup> libraries were designed by targeting six active site loops that play a role in substrate binding<sup>24</sup> and mutating 9 - 11 residues located around the active site (Figures 2A and S7). Randomization was achieved using a Slonomics approach,<sup>25</sup> resulting in approximately three mutations per gene

(Figure S8) and library sizes of up to  $10^{14}$  variants. These six Savinase<sup>®</sup> libraries were interrogated (Figures 2C, 2E and S9): 500,000 to 4,000,000 droplets were screened to yield 34 to 200 hits per library (Table S2). For lib-1 0.02% of the droplets were selected and for lib-6 0.004% of the population, respectively. This value depends on the presence of highly active variants within the library screened and the detection threshold set up at the beginning of the selection. In general, the sorting gate was set up, so that droplets showing increased fluorescence over the population average were selected. The selected droplets were subsequently de-emulsified and DNA (i.e. of long

concatemers resulting from RCA) was recovered. For low-throughput re-screening, these hits were expressed in the original producer, *B. subtilis*. After PCR amplification of the recovered hit DNA and cloning into the expression and secretion vector pCri18a, *B. subtilis* was transformed. Resulting transformants were screened in 96-well plates for hydrolysis of the fluorogenic casein substrate that has been used for the screening in droplets. Re-screening 88 randomly picked colonies of



**Figure 3.** Screening of Savinase<sup>®</sup> library created by re-shuffling of mutants obtained in a first screen (Figure S12). (A) Histogram of the fluorescence signal distribution of droplets screened for Savinase<sup>®</sup> activity after three days of incubation at room temperature in darkness. The sorting gate was set up, so that droplets showing increased fluorescence over the population average were selected (shown in green). (B) Activities of five identified shuffled variants against the fluorogenic casein substrate are shown. The activity for each shuffled variant is plotted relative to that of sav-wt. (C) Time-course of shuffled variant G10+E2 showing highest activity towards the substrate casein in comparison to parents and wildtype.

*B. subtilis*, purified and further tested against the fluorogenic casein substrate (Figure S11). From six libraries 16 variants were found to be the most active ones, exhibiting up to 3-fold improvements on their initial rates  $v_0$  (Figure S12). The different mutations observed are shown in Table S3 (see SI). Overall, two to four mutations per gene were found (matching the expected mutation rates; Figure S8). In 10 out of the 16 variants selected, residues were found to be mutated to arginine or lysine. These two positively charged basic amino acids are mostly exposed to the protein surface and play important roles in protein stability by forming electrostatic interactions.<sup>26</sup> The pI of the substrate casein has been determined to be 4.6, so that its surface at pH values around 8 is negatively charged. Savinase with a pI of 10 has a positive surface charge at this pH, so replacement of negatively charged or neutral residues by positively charged basic amino acids arginine and lysine slightly enhances this charge, potentially promoting enzyme-substrate interaction driven by electrostatic attraction.

To accumulate beneficial mutations identified during the screening campaign and select for synergistic effects, a shuffled library was generated *via* staggered extension process (StEP).<sup>27</sup> The shuffled library was screened on our new ultrahigh-throughput droplet screening platform (Figure 3A). 0.09% of the population passed the selection threshold and were selected, resulting in 100 hits (Table S2). Re-screening in microtiter plates and sequencing identified five shuffled variants with up to 5.5-fold increased activity compared to the wildtype (Figures 3B, 3C, S13 and S14). Previous directed evolution campaigns and engineering of subtilisin-like proteases<sup>28</sup> had only achieved improvements in biophysical properties, namely

the six Savinase<sup>®</sup> libraries before and after sorting shows an enrichment of variants with higher activity than sav-wt from 1% to 53% for lib-1 and 8% to 56% for lib-6 (Figures 2D, 2F and S10). Sequencing of the hits from each library identified during the re-screening revealed 58 unique sequences in total. These Savinase<sup>®</sup> variants were recombinantly produced in

temperature stability,<sup>29</sup> cold-adaptation,<sup>30, 31</sup> tolerance to co-solvent,<sup>32</sup> or specificity changes at the expense of activity.<sup>33, 34</sup>

In conclusion, a cell-free ultrahigh-throughput screening platform for the directed evolution of subtilisin Savinase<sup>®</sup> in droplets has been established. Stepwise DNA amplification, IVTT and substrate conversion in droplets have provided the basis for *in vitro* evolution in droplets, overcoming the previous inability to carry out *in vitro* evolution campaigns in this format, by removing cross-inhibition effects of reagents and careful choice of reaction conditions. The *integration* of multiple steps into a robust workflow with automated processing and screening of ‘monoclonal’ droplets (each representing one library member) and the efficient recovery of hits has been key to the success of this approach. A cytotoxic protease that could not be evolved in *E. coli* or yeast was substantially improved in two rounds of screening, with a large number of > 50 hits recovered to allow further improvement by re-shuffling.

Using *B. subtilis* as an alternative host for secretion of proteases (e.g. in microtiter plates) would be limited by the poor transformation efficiency of this host: merely a few hundred transformants per  $\mu\text{g}$  DNA are possible,<sup>15</sup> effectively reducing library size. By contrast, the complete absence of a transformation barrier when working in droplets makes multiple rounds of mutation/recombination and screening with larger libraries possible. *In vitro* droplet screening may also prove advantageous for functional screening of environmental libraries. Previous discovery campaigns of metagenomic proteases<sup>35-37</sup> were based on agar plate screenings. Using our cell-free workflow the throughput would be improved 100-fold and the

absence of potential incompatibility with host organisms should lead to more hits.

Practically this strategy is highly economical: Compared to screening in microtiter plates RCA and IVTT reagents are 150,000-fold reduced, allowing the screening of  $10^6$  genes using only 140  $\mu$ L of RCA mix and IVTT components. This approach will help to put currently impossible experiments in directed evolution and metagenomic screening into reality, enlarging the list of practically discoverable or evolvable candidates to other cytotoxic or membrane proteins, combined with the degrees of freedom to create non-natural reaction conditions (including the introduction of non-natural amino acids or cofactors) and apply freely chosen selection pressure in droplets.

## ASSOCIATED CONTENT

Experimental procedures (chip design, device operation, screening workflow, DNA recovery), and results (sequencing results, hit analysis) are attached as Supplementary Information (SI).

## AUTHOR INFORMATION

### Corresponding Author

\* Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge, CB2 1GA, UK; email: fh111@cam.ac.uk.

### Present Addresses

† Novozymes A/S. Krogshoejvej 36, 2880 Bagsvaerd, Denmark.

### Author Contributions

J.M.H., C.G. and F.H. designed research, J.M.H and C.G. performed research, J.M.H., C.G. and F.H. analyzed data and J.M.H. and F.H. wrote the manuscript. All authors have given approval to the final version of the manuscript.

### Funding Sources

EPSRC (EP/H046593/1). EU HORIZON 2020 (Metafluidics, 685474); EU FP7 IAPP HOTDROPS (324439). FH is an ERC Advanced Investigator (695669).

## ACKNOWLEDGMENT

The authors thank Mario Juhas for providing the 168 Marburg B. subtilis strain, Philip Mair for help with FADS, Novozymes for providing Savinase<sup>®</sup> libraries, Marko Hyvonen of the gift of the pHAT vector and the Hollfelder group for comments on the manuscript.

## ABBREVIATIONS

FADS, fluorescence-activated droplet sorting; IVTT, in vitro transcription and translation; sav-wt, Savinase<sup>®</sup> wildtype; RCA, rolling circle amplification.

## REFERENCES

1. Romero, P. A.; Arnold, F. H., Exploring protein fitness landscapes by directed evolution. *Nat Rev Mol Cell Biol* **2009**, *10* (12), 866-76.
2. Tawfik, D. S.; Griffiths, A. D., Man-made cell-like compartments for molecular evolution. *Nat Biotechnol* **1998**, *16* (7), 652-6.

3. Mair, P.; Gielen, F.; Hollfelder, F., Exploring sequence space in search of functional enzymes using microfluidic droplets. *Curr Opin Chem Biol* **2017**, *37*, 137-144.
4. Colin, P. Y.; Zinchenko, A.; Hollfelder, F., Enzyme engineering in biomimetic compartments. *Curr Opin Struct Biol* **2015**, *33*, 42-51.
5. Markel, U.; Essani, K. D.; Besirlioglu, V.; Schiffls, J.; Streit, W. R.; Schwaneberg, U., Advances in ultrahigh-throughput screening for directed enzyme evolution. *Chem Soc Rev* **2020**, *49* (1), 233-262.
6. Neun, S.; Zurek, P.; Kaminski, T.; Hollfelder, F., Ultrahigh throughput screening for enzyme function in droplets. *Meth. Enz.* **2020**, *643*, 317-343.
7. Lu, W. C.; Levy, M.; Kincaid, R.; Ellington, A. D., Directed evolution of the substrate specificity of biotin ligase. *Biotechnol Bioeng* **2014**, *111* (6), 1071-81.
8. Fallah-Araghi, A.; Baret, J. C.; Rycckelynck, M.; Griffiths, A. D., A completely in vitro ultrahigh-throughput droplet-based microfluidic screening system for protein engineering and directed evolution. *Lab Chip* **2012**, *12* (5), 882-91.
9. Holland-Moritz, D. A.; Wismer, M. K.; Mann, B. F.; Farasat, I.; Devine, P.; Guetschow, E. D.; Mangion, I.; Welch, C. J.; Moore, J. C.; Sun, S.; Kennedy, R. T., Mass Activated Droplet Sorting (MADS) Enables High-Throughput Screening of Enzymatic Reactions at Nanoliter Scale. *Angew Chem Int Ed Engl* **2020**, *59* (11), 4470-4477.
10. Courtois, F.; Olguin, L. F.; Whyte, G.; Bratton, D.; Huck, W. T.; Abell, C.; Hollfelder, F., An integrated device for monitoring time-dependent in vitro expression from single genes in picolitre droplets. *ChemBiochem* **2008**, *9* (3), 439-46.
11. Mazutis, L.; Araghi, A. F.; Miller, O. J.; Baret, J. C.; Frenz, L.; Janoshazi, A.; Taly, V.; Miller, B. J.; Hutchison, J. B.; Link, D.; Griffiths, A. D.; Rycckelynck, M., Droplet-based microfluidic systems for high-throughput single DNA molecule isothermal amplification and analysis. *Anal Chem* **2009**, *81* (12), 4813-21.
12. Betzel, C.; Klupsch, S.; Papendorf, G.; Hastrup, S.; Branner, S.; Wilson, K. S., Crystal structure of the alkaline proteinase Savinase from *Bacillus lentus* at 1.4 Å resolution. *J Mol Biol* **1992**, *223* (2), 427-45.
13. Li, Q.; Yi, L.; Marek, P.; Iverson, B. L., Commercial proteases: present and future. *FEBS Lett* **2013**, *587* (8), 1155-63.
14. Vojcic, L.; Pitzler, C.; Korfer, G.; Jakob, F.; Ronny, M.; Maurer, K. H.; Schwaneberg, U., Advances in protease engineering for laundry detergents. *N Biotechnol* **2015**, *32* (6), 629-34.
15. Vojcic, L.; Despotovic, D.; Martinez, R.; Maurer, K. H.; Schwaneberg, U., An efficient transformation method for *Bacillus subtilis* DB104. *Appl Microbiol Biotechnol* **2012**, *94* (2), 487-93.
16. Fire, A.; Xu, S. Q., Rolling replication of short DNA circles. *Proc Natl Acad Sci U S A* **1995**, *92* (10), 4641-5.
17. Schaeferli, Y.; Wootton, R. C.; Robinson, T.; Stein, V.; Dunsby, C.; Neil, M. A.; French, P. M.; Demello, A. J.; Abell, C.; Hollfelder, F., Continuous-flow polymerase chain reaction of single-copy DNA in microfluidic microdroplets. *Anal Chem* **2009**, *81* (1), 302-6.
18. Shimizu, Y.; Inoue, A.; Tomari, Y.; Suzuki, T.; Yokogawa, T.; Nishikawa, K.; Ueda, T., Cell-free translation reconstituted with purified components. *Nat Biotechnol* **2001**, *19* (8), 751-5.
19. Abate, A. R.; Hung, T.; Mary, P.; Agresti, J. J.; Weitz, D. A., High-throughput injection with microfluidics using picoinjectors. *Proc Natl Acad Sci U S A* **2010**, *107* (45), 19163-6.
20. Baret, J. C.; Miller, O. J.; Taly, V.; Rycckelynck, M.; El-Harrak, A.; Frenz, L.; Rick, C.; Samuels, M. L.; Hutchison, J. B.; Agresti, J. J.; Link, D. R.; Weitz, D. A.; Griffiths, A. D., Fluorescence-activated droplet sorting (FADS): efficient microfluidic cell sorting based on enzymatic activity. *Lab Chip* **2009**, *9* (13), 1850-8.
21. Colin, P. Y.; Kintses, B.; Gielen, F.; Miton, C. M.; Fischer, G.; Mohamed, M. F.; Hyvonen, M.; Morgavi, D. P.; Janssen, D. B.;

- Hollfelder, F., Ultrahigh-throughput discovery of promiscuous enzymes by picodroplet functional metagenomics. *Nat Commun* **2015**, *6*, 10008.
22. Kintsjes, B.; van Vliet, L. D.; Devenish, S. R.; Hollfelder, F., Microfluidic droplets: new integrated workflows for biological experiments. *Curr Opin Chem Biol* **2010**, *14* (5), 548-55.
23. Zinchenko, A.; Devenish, S. R.; Kintsjes, B.; Colin, P. Y.; Fischlechner, M.; Hollfelder, F., One in a million: flow cytometric sorting of single cell-lysate assays in monodisperse picolitre double emulsion droplets for directed evolution. *Anal Chem* **2014**, *86* (5), 2526-33.
24. Brode, P. F.; Barnett, B. L.; Rubingh, D. N.; Ghosh, C. K. Subtilisin 309 variants having decreased adsorption and increased hydrolysis. Patent no WO1995030011A2, **1994**.
25. Van den Brulle, J.; Fischer, M.; Langmann, T.; Horn, G.; Waldmann, T.; Arnold, S.; Fuhrmann, M.; Schatz, O.; O'Connell, T.; O'Connell, D.; Auckenthaler, A.; Schwer, H., A novel solid phase technology for high-throughput gene synthesis. *Biotechniques* **2008**, *45* (3), 340-3.
26. Sokalingam, S.; Raghunathan, G.; Soundrarajan, N.; Lee, S. G., A study on the effect of surface lysine to arginine mutagenesis on protein stability and structure using green fluorescent protein. *PLoS One* **2012**, *7* (7), e40410.
27. Zhao, H.; Giver, L.; Shao, Z.; Affholter, J. A.; Arnold, F. H., Molecular evolution by staggered extension process (StEP) in vitro recombination. *Nat Biotechnol* **1998**, *16* (3), 258-61.
28. Bryan, P. N., Protein engineering of subtilisin. *Biochim Biophys Acta* **2000**, *1543* (2), 203-222.
29. Zhao, H.; Arnold, F. H., Directed evolution converts subtilisin E into a functional equivalent of thermitase. *Protein Eng* **1999**, *12* (1), 47-53.
30. Tindbaek, N.; Svendsen, A.; Oestergaard, P. R.; Draborg, H., Engineering a substrate-specific cold-adapted subtilisin. *Protein Eng Des Sel* **2004**, *17* (2), 149-56.
31. Pulido, M. A.; Koga, Y.; Takano, K.; Kanaya, S., Directed evolution of Tk-subtilisin from a hyperthermophilic archaeon: identification of a single amino acid substitution responsible for low-temperature adaptation. *Protein Eng Des Sel* **2007**, *20* (3), 143-53.
32. You, L.; Arnold, F. H., Directed evolution of subtilisin E in *Bacillus subtilis* to enhance total activity in aqueous dimethylformamide. *Protein Eng* **1996**, *9* (1), 77-83.
33. Legendre, D.; Laraki, N.; Graslund, T.; Bjornvad, M. E.; Bouchet, M.; Nygren, P. A.; Borchert, T. V.; Fastrez, J., Display of active subtilisin 309 on phage: analysis of parameters influencing the selection of subtilisin variants with changed substrate specificity from libraries using phosphonylating inhibitors. *J Mol Biol* **2000**, *296* (1), 87-102.
34. Bonneau, P. R.; Graycar, T. P.; Estell, D. A.; Jones, J. B., Alteration of the specificity of subtilisin BPN' by site-directed mutagenesis in its S1 and S1' binding sites. *J. Am. Chem. Soc.* **1991**, *113* (3), 1026-30.
35. Pushpam, P. L.; Rajesh, T.; Gunasekaran, P., Identification and characterization of alkaline serine protease from goat skin surface metagenome. *AMB Express* **2011**, *1* (1), 3.
36. Pessoa, T. B. A.; Rezende, R. P.; Marques, E. L. S.; Pirovani, C. P.; Dos Santos, T. F.; Dos Santos Goncalves, A. C.; Romano, C. C.; Dotivo, N. C.; Freitas, A. C. O.; Salay, L. C.; Dias, J. C. T., Metagenomic alkaline protease from mangrove sediment. *J Basic Microbiol* **2017**, *57* (11), 962-973.
37. Neveu, J.; Regeard, C.; DuBow, M. S., Isolation and characterization of two serine proteases from metagenomic libraries of the Gobi and Death Valley deserts. *Appl Microbiol Biotechnol* **2011**, *91* (3), 635-44.